2024
Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data
Torgersen J, Mezochow A, Newcomb C, Carbonari D, Hennessy S, Rentsch C, Park L, Tate J, Bräu N, Bhattacharya D, Lim J, Mezzacappa C, Njei B, Roy J, Taddei T, Justice A, Re V. Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data. JAMA Internal Medicine 2024, 184: 943-952. PMID: 38913369, PMCID: PMC11197444, DOI: 10.1001/jamainternmed.2024.1836.Peer-Reviewed Original ResearchIncidence rateUS Department of Veterans AffairsMedication initiationDepartment of Veterans AffairsInitiation of medicationVeterans AffairsMain OutcomesPotential of medicationsOutpatient settingDischarge diagnosisCohort studyDay of admissionCase reportReal World DataReport countsMedicationMedical cohortSevere acute liver injuryUS DepartmentFollow-upAcute liver injuryHospitalCohortHepatotoxic medicationsIncidenceContribution of Potentially Inappropriate Medications to Polypharmacy-Associated Risk of Mortality in Middle-Aged Patients: A National Cohort Study
Guillot J, Justice A, Gordon K, Skanderson M, Pariente A, Bezin J, Rentsch C. Contribution of Potentially Inappropriate Medications to Polypharmacy-Associated Risk of Mortality in Middle-Aged Patients: A National Cohort Study. Journal Of General Internal Medicine 2024, 1-10. PMID: 38831248, DOI: 10.1007/s11606-024-08817-4.Peer-Reviewed Original ResearchMiddle-aged patientsRisk of mortalityVeterans AffairsChronic medicationsVA patient populationIntegrated healthcare systemNational cohort studyAssociated with increased mortalityMiddle-aged individualsMechanism of injuryMiddle-aged peopleAssociated with mortalityInappropriate medicationsBeers criteriaHealthcare systemAttenuate riskCohort studyClinical characteristicsGeneral populationHyperpolypharmacyFollow-upPolypharmacyPatient populationBackgroundThe roleCox modelOpenSAFELY: A platform for analysing electronic health records designed for reproducible research
Nab L, Schaffer A, Hulme W, DeVito N, Dillingham I, Wiedemann M, Andrews C, Curtis H, Fisher L, Green A, Massey J, Walters C, Higgins R, Cunningham C, Morley J, Mehrkar A, Hart L, Davy S, Evans D, Hickman G, Inglesby P, Morton C, Smith R, Ward T, O'Dwyer T, Maude S, Bridges L, Butler‐Cole B, Stables C, Stokes P, Bates C, Cockburn J, Hester F, Parry J, Bhaskaran K, Schultze A, Rentsch C, Mathur R, Tomlinson L, Williamson E, Smeeth L, Walker A, Bacon S, MacKenna B, Goldacre B. OpenSAFELY: A platform for analysing electronic health records designed for reproducible research. Pharmacoepidemiology And Drug Safety 2024, 33: e5815-e5815. PMID: 38783412, PMCID: PMC7616137, DOI: 10.1002/pds.5815.Peer-Reviewed Original ResearchConceptsElectronic health recordsHealth recordsComputing environmentProgram codeSoftware platformAdministrative health dataAnalysis environmentAudit trailReproducibility of researchReproducible researchData preparationPublic sharingPublic health guidanceHealth dataHealth guidanceCodeOpenSAFELYTechnical solutionsPlatformPromote trustCOVID-19 pandemicIncrease transparencyCode-sharingWorkflowDataCare interruptions and mortality among adults in Europe and North America
Trickey A, Zhang L, Rentsch C, Pantazis N, Izquierdo R, Antinori A, Leierer G, Burkholder G, Cavassini M, Palacio-Vieira J, Gill M, Teira R, Stephan C, Obel N, Vehreschild J, Sterling T, Van Der Valk M, Bonnet F, Crane H, Silverberg M, Ingle S, Sterne J. Care interruptions and mortality among adults in Europe and North America. AIDS 2024, 38: 1533-1542. PMID: 38742863, PMCID: PMC11239093, DOI: 10.1097/qad.0000000000003924.Peer-Reviewed Original ResearchCare interruptionsMortality riskCohort studyHazard ratioAnalysis of cohort studiesAntiretroviral therapyCare of peopleRobust to sensitivity analysesMortality hazard ratioCrude mortality rateHazard of mortalityAntiretroviral therapy initiationObservational cohort studyAntiretroviral therapy startUninterrupted careFollow-up groupCareAssociated with adverse outcomesPWHCox regressionAdverse outcomesFollow-up timeMortality rateCompare hazardsComposite outcomeAuthor Correction: A multi-ancestry genetic study of pain intensity in 598,339 veterans
Toikumo S, Vickers-Smith R, Jinwala Z, Xu H, Saini D, Hartwell E, Pavicic M, Sullivan K, Xu K, Jacobson D, Gelernter J, Rentsch C, Stahl E, Cheatle M, Zhou H, Waxman S, Justice A, Kember R, Kranzler H. Author Correction: A multi-ancestry genetic study of pain intensity in 598,339 veterans. Nature Medicine 2024, 30: 2088-2088. PMID: 38714900, DOI: 10.1038/s41591-024-03024-4.Peer-Reviewed Original ResearchQuantifying possible bias in clinical and epidemiological studies with quantitative bias analysis: common approaches and limitations
Brown J, Hunnicutt J, Ali M, Bhaskaran K, Cole A, Langan S, Nitsch D, Rentsch C, Galwey N, Wing K, Douglas I. Quantifying possible bias in clinical and epidemiological studies with quantitative bias analysis: common approaches and limitations. The BMJ 2024, 385: e076365. PMID: 38565248, DOI: 10.1136/bmj-2023-076365.Peer-Reviewed Original ResearchA multi-ancestry genetic study of pain intensity in 598,339 veterans
Toikumo S, Vickers-Smith R, Jinwala Z, Xu H, Saini D, Hartwell E, Pavicic M, Sullivan K, Xu K, Jacobson D, Gelernter J, Rentsch C, Stahl E, Cheatle M, Zhou H, Waxman S, Justice A, Kember R, Kranzler H. A multi-ancestry genetic study of pain intensity in 598,339 veterans. Nature Medicine 2024, 30: 1075-1084. PMID: 38429522, DOI: 10.1038/s41591-024-02839-5.Peer-Reviewed Original ResearchPain intensityChronic painTreat chronic painCalcium channel blockersCross-ancestry meta-analysisGenome-wide association studiesExperience of painSamples of European ancestryPain phenotypesFunctional genomics dataGABAergic neuronsCalcium channelsAnalgesic effectB-blockersDrug groupMillion Veteran ProgramPainSubstance use disordersQuality of lifeDrug repurposing analysisOpioid crisisGenetic architectureCausal genesGenetic lociGenomic dataIncident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records
Doran W, Tunnicliffe L, Muzambi R, Rentsch C, Bhaskaran K, Smeeth L, Brayne C, Williams D, Chaturvedi N, Eastwood S, Dunachie S, Mathur R, Warren-Gash C. Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records. BMJ Open Diabetes Research & Care 2024, 12: e003548. PMID: 38272537, PMCID: PMC10823924, DOI: 10.1136/bmjdrc-2023-003548.Peer-Reviewed Original ResearchConceptsRisk of dementiaMild cognitive impairmentOral glucose-lowering therapyDementia riskObservational cohort studyAs-treated analysisGlucose-lowering therapyRisk of incident all-cause dementiaUK adultsCompare risk of dementiaIncident all-cause dementiaType 2 diabetesClinical Practice Research DatalinkActive comparator new user designCohort studyAll-cause dementiaPrimary healthcare recordsIncident dementia riskAssociated with lower riskPotential exposure misclassificationCox proportional hazards regressionMetformin useRisk of confoundingProportional hazards regressionIncident dementiaPsychotropic prescribing after hospital discharge in survivors of critical illness, a retrospective cohort study (2012–2019)
Mansi E, Rentsch C, Bourne R, Guthrie B, Lone N. Psychotropic prescribing after hospital discharge in survivors of critical illness, a retrospective cohort study (2012–2019). Journal Of The Intensive Care Society 2024, 25: 171-180. PMID: 38737305, PMCID: PMC11081855, DOI: 10.1177/17511437231223470.Peer-Reviewed Original ResearchPsychotropic prescriptionsSurvivors of critical illnessCritical care survivorsPsychotropic prescribingCare groupHospital dischargeRetrospective cohort studyCritical careCritical illnessCohort studyHazard ratioMental health issuesCritical care groupHospitalised survivorsPsychotropic medicinesPotential confoundersSleep disturbanceHospitalised adultsHealth issuesHospitalised patientsIllnessSurvivorsPrescriptionClinical practiceCareHypertension Control During the Coronavirus Disease 2019 Pandemic
Korves C, Peixoto A, Lucas B, Davies L, Weinberger D, Rentsch C, Vashi A, Young-Xu Y, King J, Asch S, Justice A. Hypertension Control During the Coronavirus Disease 2019 Pandemic. Medical Care 2024, 62: 196-204. PMID: 38284412, PMCID: PMC10922611, DOI: 10.1097/mlr.0000000000001971.Peer-Reviewed Original ResearchConceptsHypertension controlFollow-up intervalPrimary care clinic visitsFollow-up lengthVeterans Health AdministrationControlled hypertensionUncontrolled hypertensionGeneralized estimating equationsCohort of individualsStudy inclusion criteriaHealth careHealth AdministrationLonger follow-up intervalsBlood pressure measurementsAssessed associationsClinic visitsInclusion criteriaDecreased likelihoodEstimating equationsPrepandemic periodLow likelihoodCoronavirus diseaseFollow-upHypertensionIndividualsHerpes Zoster and Risk of Incident Parkinson's Disease in US Veterans: A Matched Cohort Study
Tunnicliffe L, Weil R, Breuer J, Rodriguez‐Barradas M, Smeeth L, Rentsch C, Warren‐Gash C. Herpes Zoster and Risk of Incident Parkinson's Disease in US Veterans: A Matched Cohort Study. Movement Disorders 2024, 39: 438-444. PMID: 38226430, PMCID: PMC10922272, DOI: 10.1002/mds.29701.Peer-Reviewed Original ResearchConceptsUS Department of Veterans AffairsCohort studyRisk of incident PDDepartment of Veterans AffairsCox proportional hazards regressionIncident Parkinson's diseaseAssociated with increased riskHistory of HZMatched cohort studyProportional hazards regressionRisk of PDHerpes zosterIncident PDRisk of incident Parkinson's diseaseVeterans AffairsIncident HZUS veteransPD overallHazards regressionPD riskParkinson's diseaseIncreased riskMatched individualsUS DepartmentAssociated with Parkinson's disease
2023
Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants
Wang A, Shen J, Rodriguez A, Saunders E, Chen F, Janivara R, Darst B, Sheng X, Xu Y, Chou A, Benlloch S, Dadaev T, Brook M, Plym A, Sahimi A, Hoffman T, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Laisk T, Figuerêdo J, Muir K, Ito S, Liu X, Uchio Y, Kubo M, Kamatani Y, Lophatananon A, Wan P, Andrews C, Lori A, Choudhury P, Schleutker J, Tammela T, Sipeky C, Auvinen A, Giles G, Southey M, MacInnis R, Cybulski C, Wokolorczyk D, Lubinski J, Rentsch C, Cho K, Mcmahon B, Neal D, Donovan J, Hamdy F, Martin R, Nordestgaard B, Nielsen S, Weischer M, Bojesen S, Røder A, Stroomberg H, Batra J, Chambers S, Horvath L, Clements J, Tilly W, Risbridger G, Gronberg H, Aly M, Szulkin R, Eklund M, Nordstrom T, Pashayan N, Dunning A, Ghoussaini M, Travis R, Key T, Riboli E, Park J, Sellers T, Lin H, Albanes D, Weinstein S, Cook M, Mucci L, Giovannucci E, Lindstrom S, Kraft P, Hunter D, Penney K, Turman C, Tangen C, Goodman P, Thompson I, Hamilton R, Fleshner N, Finelli A, Parent M, Stanford J, Ostrander E, Koutros S, Beane Freeman L, Stampfer M, Wolk A, Håkansson N, Andriole G, Hoover R, Machiela M, Sørensen K, Borre M, Blot W, Zheng W, Yeboah E, Mensah J, Lu Y, Zhang H, Feng N, Mao X, Wu Y, Zhao S, Sun Z, Thibodeau S, McDonnell S, Schaid D, West C, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel A, Drake B, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou Y, John E, Grindedal E, Maehle L, Khaw K, Ingles S, Stern M, Vega A, Gómez-Caamaño A, Fachal L, Rosenstein B, Kerns S, Ostrer H, Teixeira M, Paulo P, Brandão A, Watya S, Lubwama A, Bensen J, Butler E, Mohler J, Taylor J, Kogevinas M, Dierssen-Sotos T, Castaño-Vinyals G, Cannon-Albright L, Teerlink C, Huff C, Pilie P, Yu Y, Bohlender R, Gu J, Strom S, Multigner L, Blanchet P, Brureau L, Kaneva R, Slavov C, Mitev V, Leach R, Brenner H, Chen X, Holleczek B, Schöttker B, Klein E, Hsing A, Kittles R, Murphy A, Logothetis C, Kim J, Neuhausen S, Steele L, Ding Y, Isaacs W, Nemesure B, Hennis A, Carpten J, Pandha H, Michael A, De Ruyck K, De Meerleer G, Ost P, Xu J, Razack A, Lim J, Teo S, Newcomb L, Lin D, Fowke J, Neslund-Dudas C, Rybicki B, Gamulin M, Lessel D, Kulis T, Usmani N, Abraham A, Singhal S, Parliament M, Claessens F, Joniau S, Van den Broeck T, Gago-Dominguez M, Castelao J, Martinez M, Larkin S, Townsend P, Aukim-Hastie C, Bush W, Aldrich M, Crawford D, Srivastava S, Cullen J, Petrovics G, Casey G, Wang Y, Tettey Y, Lachance J, Tang W, Biritwum R, Adjei A, Tay E, Truelove A, Niwa S, Yamoah K, Govindasami K, Chokkalingam A, Keaton J, Hellwege J, Clark P, Jalloh M, Gueye S, Niang L, Ogunbiyi O, Shittu O, Amodu O, Adebiyi A, Aisuodionoe-Shadrach O, Ajibola H, Jamda M, Oluwole O, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Diop H, Gundell S, Roobol M, Jenster G, van Schaik R, Hu J, Sanderson M, Kachuri L, Varma R, McKean-Cowdin R, Torres M, Preuss M, Loos R, Zawistowski M, Zöllner S, Lu Z, Van Den Eeden S, Easton D, Ambs S, Edwards T, Mägi R, Rebbeck T, Fritsche L, Chanock S, Berndt S, Wiklund F, Nakagawa H, Witte J, Gaziano J, Justice A, Mancuso N, Terao C, Eeles R, Kote-Jarai Z, Madduri R, Conti D, Haiman C. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nature Genetics 2023, 55: 2065-2074. PMID: 37945903, PMCID: PMC10841479, DOI: 10.1038/s41588-023-01534-4.Peer-Reviewed Original ResearchConceptsGenome-wide association studiesMulti-ancestry genome-wide association studyNovel risk variantsRisk variantsAssociation studiesProstate cancer genome-wide association studiesCancer genome-wide association studyGenome-wide discoveryProstate cancer susceptibility lociGenetic risk scoreCancer susceptibility lociEuropean ancestry menGenetic studiesSusceptibility lociNon-aggressive diseaseEffective risk stratificationAfrican ancestry menProstate cancer riskAncestry groupsProstate cancer casesRisk stratificationAfrican ancestryProstate cancerCancer casesCancer riskIntegrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration
Rein S, Lodi S, Logan R, Touloumi G, Antoniadou A, Wittkop L, Bonnet F, van Sighem A, van der Valk M, Reiss P, Klein M, Young J, Jarrin I, Monforte A, Tavelli A, Meyer L, Tran L, Gill M, Lang R, Surial B, Haas A, Justice A, Rentsch C, Phillips A, Sabin C, Miro J, Trickey A, Ingle S, Sterne J, Hernán M, Collaboration A. Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration. The Lancet HIV 2023, 10: e723-e732. PMID: 37923486, PMCID: PMC10695103, DOI: 10.1016/s2352-3018(23)00233-3.Peer-Reviewed Original ResearchConceptsART-experienced individualsCardiovascular eventsTarget trialsART regimensRisk ratioTreatment strategiesRisk differenceEligibility criteriaIntegrase strand transfer inhibitor useAntiretroviral Therapy Cohort CollaborationIntegrase strand transfer inhibitorsPooled logistic modelART-naive individualsHIV RNA measurementsHIV-CAUSAL CollaborationNational InstituteStrand transfer inhibitorsLogistic regression modelsART regimenCohort CollaborationAntiretroviral therapyInhibitor useBlood pressureINSTI useClinical dataExcess mortality in US Veterans during the COVID-19 pandemic: an individual-level cohort study
Weinberger D, Bhaskaran K, Korves C, Lucas B, Columbo J, Vashi A, Davies L, Justice A, Rentsch C. Excess mortality in US Veterans during the COVID-19 pandemic: an individual-level cohort study. International Journal Of Epidemiology 2023, 52: 1725-1734. PMID: 37802889, PMCID: PMC10749763, DOI: 10.1093/ije/dyad136.Peer-Reviewed Original ResearchConceptsExcess mortality ratesExcess mortalityComorbidity burdenHazard ratioCohort studyMortality rateVeterans Aging Cohort Study (VACS) IndexIndividual-level cohort studyVeterans AffairsCOVID-19 pandemicLarge integrated healthcare systemExcess mortality patternsHigher comorbidity burdenLower comorbidity burdenMost frail patientsCharlson Comorbidity IndexObservational cohort studyClinical risk groupsIntegrated healthcare systemLeast frailComorbidity indexFrail patientsPre-pandemic periodMedian ageUS veteransT102. IDENTIFYING NEW TREATMENT TARGETS FOR ALCOHOL USE DISORDER THROUGH GENETIC AND ELECTRONIC HEALTH RECORDS DATA APPROACHES
Gray J, Kranzler H, Leggio L, Piserchia Z, Winterlind E, Setzer M, Rentsch C. T102. IDENTIFYING NEW TREATMENT TARGETS FOR ALCOHOL USE DISORDER THROUGH GENETIC AND ELECTRONIC HEALTH RECORDS DATA APPROACHES. European Neuropsychopharmacology 2023, 75: s217. DOI: 10.1016/j.euroneuro.2023.08.386.Peer-Reviewed Original ResearchSeed genesGenome-wide significant lociL-type calcium channel blockerDisease-associated genesCalcium channel blockersAlcohol use disorderTargets of approved drugsPeripheral genesSignificant lociCausal genesGene identificationGene inputNetwork genesGenetic supportBiological networksChannel blockersGenesUse disorderDisease mechanismsFDA-approved drugsL-type calcium channelsRegulate dopamine activityImprove drug developmentAlpha-adrenergic receptorsSevere side effectsAlcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy
Cartwright E, Pierret C, Minassian C, Esserman D, Tate J, Goetz M, Bhattacharya D, Fiellin D, Justice A, Re V, Rentsch C. Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy. JAMA Network Open 2023, 6: e2335715. PMID: 37751206, PMCID: PMC10523171, DOI: 10.1001/jamanetworkopen.2023.35715.Peer-Reviewed Original ResearchConceptsSustained virologic responseAlcohol use disorderHigh-risk consumptionHistory of AUDLow-risk consumptionDAA therapyAlcohol use categoriesAlcohol useVirologic responseCohort studyAntiviral therapyOdds ratioChronic hepatitis C virus (HCV) infectionAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionVeterans AffairsActing antiviral (DAA) therapyDAA treatment initiationHCV elimination goalsUndetectable HCV RNAC virus infectionFibrosis-4 scoreRetrospective cohort studyMultivariable logistic regressionTenth Revision diagnosisSex-specific risks for cardiovascular disease across the glycaemic spectrum: a population-based cohort study using the UK Biobank
Rentsch C, Garfield V, Mathur R, Eastwood S, Smeeth L, Chaturvedi N, Bhaskaran K. Sex-specific risks for cardiovascular disease across the glycaemic spectrum: a population-based cohort study using the UK Biobank. The Lancet Regional Health - Europe 2023, 32: 100693. PMID: 37671124, PMCID: PMC10477037, DOI: 10.1016/j.lanepe.2023.100693.Peer-Reviewed Original ResearchCoronary artery diseaseDeep vein thrombosisSex-specific riskCardiovascular diseaseUndiagnosed diabetesGlycaemic spectrumPulmonary embolismExcess riskPopulation-based cohort studyRisk of CVDAge-adjusted HRIncident cardiovascular diseaseBritish Heart FoundationSex-specific associationsUK BiobankWeight reduction strategiesStatin medicationStatin useClinical characteristicsCohort studyComposite outcomeNormal HbA1cVein thrombosisArtery diseaseHeart failurePrognostic Factors of COVID‐19: An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology
Sarri G, Liu W, Zabotka L, Freitag A, Claire R, Wangge G, Elvidge J, Dawoud D, Bennett D, Wen X, Li X, Rentsch C, Uddin J, Ali M, Gokhale M, Déruaz‐Luyet A, Moga D, Guo J, Zullo A, Patorno E, Lin K. Prognostic Factors of COVID‐19: An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology. Clinical Pharmacology & Therapeutics 2023, 114: 604-613. PMID: 37342987, DOI: 10.1002/cpt.2977.Peer-Reviewed Original ResearchConceptsPrognostic factorsUmbrella reviewHigh riskIntensive care unit admissionShort-term adverse outcomesCOVID-19AMSTAR-2 toolSystematic literature reviewCare unit admissionRisk of hospitalizationKey prognostic factorsHigh-risk groupCoronavirus disease 2019 (COVID-19) pandemicCOVID-19 outcomesDisease 2019 pandemicComparative effectiveness researchInternational SocietyCOVID-19 disparitiesUnit admissionLong COVIDMale sexAdverse outcomesOptimal careFemale sexHeart diseaseContribution of alcohol use in HIV/hepatitis C virus co‐infection to all‐cause and cause‐specific mortality: A collaboration of cohort studies
Trickey A, Ingle S, Boyd A, Gill M, Grabar S, Jarrin I, Obel N, Touloumi G, Zangerle R, Rauch A, Rentsch C, Satre D, Silverberg M, Bonnet F, Guest J, Burkholder G, Crane H, Teira R, Berenguer J, Wyen C, Abgrall S, Hessamfar M, Reiss P, Monforte A, McGinnis K, Sterne J, Wittkop L, Collaboration T. Contribution of alcohol use in HIV/hepatitis C virus co‐infection to all‐cause and cause‐specific mortality: A collaboration of cohort studies. Journal Of Viral Hepatitis 2023, 30: 775-786. PMID: 37338017, PMCID: PMC10526649, DOI: 10.1111/jvh.13863.Peer-Reviewed Original ResearchConceptsHepatitis C virusAntiretroviral therapyAlcohol useC virusHIV/hepatitis C virusHeavy drinkersMultivariable Cox modelModerate alcohol drinkersNorth American cohortCause-specific mortalityGrams/dayBaseline alcohol useSelf-reported alcohol useHigher alcohol useART initiationHCV statusCohort studyHazard ratioAdult PWHAlcohol drinkersAlcohol use dataCox modelPWHAmerican cohortMortalityPerformance of an automated deep learning algorithm to identify hepatic steatosis within noncontrast computed tomography scans among people with and without HIV
Torgersen J, Akers S, Huo Y, Terry J, Carr J, Ruutiainen A, Skanderson M, Levin W, Lim J, Taddei T, So‐Armah K, Bhattacharya D, Rentsch C, Shen L, Carr R, Shinohara R, McClain M, Freiberg M, Justice A, Re V. Performance of an automated deep learning algorithm to identify hepatic steatosis within noncontrast computed tomography scans among people with and without HIV. Pharmacoepidemiology And Drug Safety 2023, 32: 1121-1130. PMID: 37276449, PMCID: PMC10527049, DOI: 10.1002/pds.5648.Peer-Reviewed Original ResearchConceptsSevere hepatic steatosisHepatic steatosisHIV statusLiver attenuationHounsfield unitsPredictive valueRadiologist assessmentUS Veterans Health AdministrationNoncontrast abdominal CTVeterans Health AdministrationCross-sectional studySample of patientsNegative predictive valueReal-world studyPositive predictive valueAbdominal CTLiver fatTomography scanSteatosisCT imagesHealth AdministrationPharmacoepidemiologic studiesRadiologist reviewHIVPercent agreement